Chemoreactomic analysis of magnesium- and vitamin B6-depleting drugs within the Anatomical Therapeutic Chemical classification as a basis for preventing adverse effects of pharmacotherapy

Background. Many pharmaceuticals, including antibiotics, diuretics, some antitumor agents, hormones, etc., can promote the depletion of magnesium (Mg), pyridoxine (vitamin B6, VB6), and other micronutrients (MNs) in the body. This process may lead to the development of hypomagnesemia and concomitant MN deficiencies, which are associated with a range of adverse effects, including neurotoxicity, cardiotoxicity, hepatotoxicity, etc. Moreover, the resulting micronutrient deficiency (MND) may paradoxically aggravate the underlying pathophysiological mechanisms of the diseases for which these drugs are prescribed, thereby potentially diminishing therapeutic efficacy and contributing to treatment-related complication.

Objective: Chemoreactomic assessment of anti-micronutrient (anti-MN) effects of all drugs included in the Anatomical Therapeutic Chemical (ATC) classification system.

Material and methods. Using modern data mining techniques, including mathematical approaches from topological data analysis, labeled graph theory (chemographs), and related method, this study performed a systematic computer-based analysis of databases describing the Mg-depleting effects of drugs; original algorithms for numerically predicting the Mg- and VB6-removing effects of drugs. Original algorithms were developed for the numerical prediction of Mg- and VB6-depleting properties of drugs, as well as for the assessment of other anti-MN effects. These algorithms were subsequently applied in a chemoreactomic screening of 2,527 drugs classified within the ATC system.

Results. A database describing anti-MN properties of drugs was created for 24 MN balance indicators for 18 MNs. Algorithms for predicting the anti-MN properties of drugs were developed with a classification accuracy of 92±10% in cross-validation (the accuracy of predicting VB6 MND – 88%, Mg MND – 94-98%). On average, each drug from the ATC group accounts for 8.5±6.5 anti-MN effects. Only 100 out of 2527 (4%) drugs did not exhibit a negative impact on MN, primarily amino acids, MNs themselves, and choline drugs. The most pronounced negative impact of the drugs under study was related to the metabolism of vitamin D3 (505 ATC categories), VB6 (475 ATC categories), iron (419 ATC categories), vitamin B1 (386 ATC categories), and Mg (375 ATC categories). VB6 MND was caused by 1701 drugs, Mg MND – by 1064 drugs. Antibiotics for systemic use (ATC code J01), psycholeptics (N05) and psychoanaleptics (N06), antineoplastic agents (L01), sex hormones and modulators of the reproductive system (G03), analgesics (N02), antidepressants (N06A), diuretics (C03), antihistamines for systemic use (R06A), anti-inflammatory and antirheumatic agents (M01), direct-acting antivirals (J05A), and antiepileptic agents (N03A) were found to affect adversely the homeostasis of both Mg and VB6. A detailed description of the anti-Mg and anti-VB6 properties of these drug classes was provided. The data obtained via chemoreactomic analysis were compared with that obtained by experimental and clinical studies of Mg and VB6 preparations.

Conclusion. The conducted chemoreactomic analysis provides a substantiated basis for supporting pharmacotherapy with selected medicinal preparations based on organic salts of Mg and VB6.

1. Passarelli S., Free C.M., Shepon A., et al. Global estimation of dietary micronutrient inadequacies: a modelling analysis. Lancet Glob Health. 2024; 12 (10): e1590–9. https://doi.org/10.1016/S2214-109X(24)00276-6.

2. Wang X., Dou Z., Feng S., et al. Global food nutrients analysis reveals alarming gaps and daunting challenges. Nat Food. 2023; 4 (11): 1007–17. https://doi.org/10.1038/s43016-023-00851-5.

3. Adomako E.A., Yu A.S.L. Magnesium disorders: core Curriculum 2024. Am J Kidney Dis. 2024; 83 (6): 803–15. https://doi.org/10.1053/j.ajkd.2023.10.017.

4. Moghnieh R., Khalil A., Bizri N., et al. QTc prolongation during levofloxacin and triazole combination chemoprophylaxis: prevalence and predisposing risk factors in a cohort of hematopoietic cell transplantation recipients. J Oncol Pharm Pract. 2023; 29 (3): 534–42. https://doi.org/10.1177/10781552221074016.

5. Shikh E.V., Makhova A.A., Chemeris A.V., Tormyshov I.A. Iatrogenic deficits of micronutrients. Voprosy pitaniia / Problems of Nutrition. 2021; 90 (4): 53–63 (in Russ.). https://doi.org/10.33029/0042-8833-2021-90-4-53-63.

6. Gromova O.A., Torshin I.Yu. Magnesium and the “diseases of civilization”. Moscow: GEOTAR-Media; 2018: 800 pp. (in Russ.).

7. Zorbas Y.G., Kakurin V.J., Afonin V.B., et al. Magnesium deposition and depletion in magnesium supplemented rats during and after hypokinesia and vivarium control. Biol Trace Elem Res. 2002; 86 (3): 203–16. https://doi.org/10.1385/BTER:86:3:203.

8. Quamme G.A. Renal handling of magnesium: drug and hormone interactions. Magnesium. 1986; 5 (5-6): 248–72.

9. Gromova O.A., Torshin I.Yu., Moiseev V.S. On pharmacological interactions of magnesium with antibiotics and magnesium deficiency resulting from antibiotic therapy. Therapy. 2017; 1: 135–43 (in Russ.).

10. Lameris A.L., Monnens L.A., Bindels R.J., Hoenderop J.G. Drug-induced alterations in Mg2+ homoeostasis. Clin Sci. 2012; 123 (1): 1–14. https://doi.org/10.1042/CS20120045

11. Gromova O.A., Torshin I.Yu., Kalacheva A.G., Grishina T.R. On synergism of potassium and magnesium in maintainance of myocardial function. Kardiologiia. 2016; 56 (3): 73–80 (in Russ.). https://doi.org/10.18565/cardio.2016.3.73-80 ]

12. Kuhn M., Letunic I., Jensen L.J., Bork P. The SIDER database of drugs and side effects. Nucleic Acids Res. 2016; 44 (D1): D1075–9. https://doi.org/10.1093/nar/gkv1075.

13. Torshin I.Yu., Gromova O.A., Chuchalin A.G., Zhuravlev Yu.I. Chemoreactome screening of pharmaceutical effects on SARS-CoV-2 and human virome to help decide on drug-based COVID-19 therapy. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021; 14 (2): 191–211 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.078.

14. Bolton E., Wang Y., Thiessen P.A., Bryant S.H. PubChem: integrated platform of small molecules and biological activities. In: Annual Reports in Computational Chemistry, vol. 4. American Chemical Society; 2008: 217–41.

15. Wishart D.S., Tzur D., Knox C., et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007; 35 (Database issue): D521–6. https://doi.org/10.1093/nar/gkl923.

16. Mering C., Jensen L., Snel B., et al. STRING: known and predicted protein–protein associations, integrated and transferred across organisms. Nucleic Acids Res. 2005; 33 (Database issue): D433–7. https://doi.org/10.1093/nar/gki005.

17. Torshin I.Y., Rudakov K.V. On the procedures of generation of numerical features over partitions of sets of objects in the problem of predicting numerical target variables. Pattern Recognit Image Anal. 2019; 29: 654–67. https://doi.org/10.1134/S1054661819040175.

18. Torshin I.Yu., Rudakov K.V. On the application of the combinatorial theory of solvability to the analysis of chemographs. Part 1: Fundamentals of modern chemical bonding theory and the concept of the chemograph. Pattern Recognit Image Anal. 2014; 24: 11–23. https://doi.org/10.1134/S1054661814010209.

19. Torshin I.Yu., Rudakov K.V. On the application of the combinatorial theory of solvability to the analysis of chemographs: Part 2: Local completeness of invariants of chemographs in view of the combinatorial theory of solvability. Pattern Recognit Image Anal. 2014; 24: 196–208. https://doi.org/10.1134/S1054661814020151.

20. Torshin I.Yu. The study of the solvability of the genome annotation problem on sets of elementary motifs. Pattern Recognit Image Anal. 2011; 21: 652–62. https://doi.org/10.1134/S1054661811040171.

21. Potter E., Reyes M., Naples J., Dal Pan G. FDA Adverse Event Reporting System (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS. Clin Pharmacol Ther. 2025; 118 (3): 567–82. https://doi.org/10.1002/cpt.3701.

22. Kopitsyna UE., Grishina T.R., Torshin I.Yu., et al. Very low magnesium levels in red blood cells as a significant factor in the etiopathogenesis of borderline disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2015; 115 (11): 85–96 (in Russ.). https://doi.org/10.17116/jnevro201511511185-96.

23. Gromova O.A., Torshin I.Yu., Rudakov K.V., et al. Magnesium deficiency is a reliable risk factor of comorbid conditions: results of a large-scale screening of magnesium status in regions of Russia. Farmateka. 2013; 6: 116–29 (in Russ.).

24. Wade R.L., Chaudhari P., Natoli J.L., et al. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex. Diagn Microbiol Infect Dis. 2013; 76 (3): 361–7. https://doi.org/10.1016/j.diagmicrobio.2013.04.001.

25. Abo-Salem E., Fowler J.C., Attari M., et al. Antibiotic-induced cardiac arrhythmias. Cardiovasc Ther. 2014; 32 (1): 19–25. https://doi.org/10.1111/1755-5922.12054

26. Ayad R.F., Assar M.D., Simpson L., et al. Causes and management of drug-induced long QT syndrome. Proc (Bayl Univ Med Cent). 2010; 23 (3): 250–5. https://doi.org/10.1080/08998280.2010.11928628.

27. Kes P., Reiner Z. Symptomatic hypomagnesemia associated with gentamicin therapy. Magnes Trace Elem. 1990; 9 (1): 54–60.

28. Liamis G., Hoorn E.J., Florentin M., Milionis H. An overview of diagnosis and management of drug-induced hypomagnesemia. Pharmacol Res Perspect. 2021; 9 (4): e00829. https://doi.org/10.1002/prp2.829.

29. Rosner M.H., Ha N., Palmer B.F., Perazella M.A. Acquired disorders of hypomagnesemia. Mayo Clin Proc. 2023; 98 (4): 581–96. https://doi.org/10.1016/j.mayocp.2022.12.002.

30. von Vigier R.O., Truttmann A.C., Zindler-Schmocker K., et al. Aminoglycosides and renal magnesium homeostasis in humans. Nephrol Dial Transplant. 2000; 15 (6): 822–6. https://doi.org/10.1093/ndt/15.6.822.

31. Kushner J.M., Peckman H.J., Snyder C.R. Seizures associated with fluoroquinolones. Ann Pharmacother. 2001; 35 (10): 1194-8. https://doi.org/10.1345/aph.10359.

32. Stahlmann R., Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010; 27 (3): 193–209. https://doi.org/10.2165/11531490-000000000-00000.

33. Shakibaei M., Kociok K., Förster C., et al. Comparative evaluation of ultrastructural changes in articular cartilage of ofloxacin-treated and magnesium-deficient immature rats. Toxicol Pathol. 1996; 24 (5): 580–7. https://doi.org/10.1177/019262339602400507.

34. Achhammer I., Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs. 1991; 41 (Suppl. 3): 80–91. https://doi.org/10.2165/00003495-199100413-00009.

35. Khow K.S., Lau S.Y., Li J.Y., Yong T.Y. Diuretic-associated electrolyte disorders in the elderly: risk factors, impact, management and prevention. Curr Drug Saf. 2014; 9 (1): 2–15. https://doi.org/10.2174/1574886308666140109112730.

36. Wile D. Diuretics: a review. Ann Clin Biochem. 2012; 49 (Pt 5): 419–31. https://doi.org/10.1258/acb.2011.011281.

37. Gromova O.A., Grishina T.R., Torshin I.Yu., et al. Diuretics induce magnesium deficiency: tactics of correction. Terapiya / Therapy. 2017; 2 (12): 122–33 (in Russ.).

38. Greger R., Lohrmann E., Schlatter E. Action of diuretics at the cellular level. Clin Nephrol. 1992; 38 (Suppl. 1): S64–8.

39. Dai L.J., Ritchie G., Kerstan D., et al. Magnesium transport in the renal distal convoluted tubule. Physiol Rev. 2001; 81 (1): 51–84. https://doi.org/10.1152/physrev.2001.81.1.51.

40. Colaneri-Day S., Rosanoff A. Clinical guideline for detection and management of magnesium deficiency in ambulatory care. Nutrients. 2025; 17 (5): 887. https://doi.org/10.3390/nu17050887.

41. Gromova O.A., Kerimkulova N.V., Torshin I.Yu., et al. Comparative study of the evidence base for the efficacy and safety of oral and transdermal forms of estrogen replacement hormone therapy in women of different ages. Russian Journal of Human Reproduction. 2013; 6: 86–96.

42. Gromova O.A., Limanova O.A., Torshin I.Yu. Systematic analysis of fundamental and clinical research, as justification for the use of estrogen-containing drugs with the preparations of magnesium and pyridoxine. Obstetrics, Gynecology and Reproduction. 2013; 7 (3): 35–50 (in Russ.).

43. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. BMJ. 1993; 306 (6883): 956–63. https://doi.org/10.1136/bmj.306.6883.956.

44. Lussana F., Zighetti M.L., Bucciarelli P., et al. Blood levels of homocysteine, folate, vitamin B6 and B12 in women using oral contraceptives compared to non-users. Thromb Res. 2003; 112 (1-2): 37–41. https://doi.org/10.1016/j.thromres.2003.11.007.

45. Morris M.S., Picciano M.F., Jacques P.F., Selhub J. Plasma pyridoxal 5'-phosphate in the US population: the National Health and Nutrition Examination Survey, 2003–2004. Am J Clin Nutr. 2008; 87 (5): 1446–54. https://doi.org/10.1093/ajcn/87.5.1446.

46. Gromova O.A., Torshin I.Yu., Kodentsova V.M. Foods: magnesium content and uptake. Terapiya / Therapy. 2016; 2 (5): 87–96 (in Russ.).

47. Lebedev V.A., Pashkov V.M., Budanov P.V. Clinical significance of magnesium deficiency in women with premenstrual syndrome. Gynecology, Obstetrics and Perinatology. 2008; 7 (1): 77–82 (in Russ.).